Research & Development

Pharmacogenomic development

ACTIVE project

Genomic Vision and Cellectis S.A. (Alternext: ALCLS), a biotech company specialising in genome engineering, have started a partnership in the domain of antiviral research. This collaboration will fit into the framework of the ACTIVE project (Application CuraTive des Infections Virales par Endonucléases: the use of endonucleases to cure viral infections).

This project is funded by a €10 million grant from the Industrial Strategic Innovation (ISI) a program of OSEO and also benefits from the contributions and expertise of the Vision Institute, Pasteur Institute and CNRS (French National Centre for Research).